Developer docs
API playgroundTry for free, no card

Search company profiles

BioFire Defense

Full company profile

uuid000g7ce

Namestring
BioFire Defense
Legal namestring
BioFire Defense, LLC
Company typeenum
Private
Founded yearint
2001
Descriptiontext

BioFire Defense, LLC is a privately held molecular diagnostics company headquartered in Salt Lake City, Utah, and operates as a wholly-owned subsidiary of the French in vitro diagnostics major bioMérieux. Founded in 2001, the company designs, manufactures, and sells PCR-based diagnostic instruments and proprietary test panels focused on two tightly related markets: syndromic infectious disease testing in clinical and public health laboratories, and field-deployable biothreat detection for military, first responder, and biosurveillance customers.

Its product architecture centers on three instrument platforms: the BIOFIRE SPOTFIRE point-of-care PCR device (results in approximately 45 minutes), the BIOFIRE FILMARRAY TORCH high-throughput laboratory system, and the battery-powered RAZOR Mk II portable PCR system, which detects up to 10 biothreat agents in roughly 30 minutes. These instruments run a menu of single-use, freeze-dried reagent pouches covering respiratory, gastrointestinal, biothreat, global fever, meningitis/encephalitis, blood culture identification, pneumonia, and tropical disease panels. The company's revenue model combines upfront instrument sales with high-margin recurring consumables and software module sales (pouch modules and Electronic Report Modules for LIS integration), supplemented by BIOFIRE SHIELD external quality control kits.

BioFire Defense goes to market through three channels: direct enterprise sales (phone-based and via the military E-CAT procurement system) for U.S. government and defense customers, a global distributor network for international markets, and a B2B e-commerce storefront. Its customer base is concentrated in government, military, public health laboratories, and CBRN/biosurveillance end users, with regulatory moats including FDA Emergency Use Authorizations and compliance with FAR/DFAR and FAR-HHSAR clauses that position the company for BARDA and Department of Defense contract work. The business is protected by a portfolio of at least nine registered patents and several registered trademarks spanning instruments, panels, control kits, and chemistry.

Short descriptiontext

BioFire Defense, a Salt Lake City-based subsidiary of bioMérieux, develops multiplex PCR-based molecular diagnostic systems (SPOTFIRE, FILMARRAY TORCH, RAZOR Mk II) and proprietary test panels for syndromic infectious disease testing and biothreat detection, serving U.S. government, military, public health, and first responder markets globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, syndromic testing, biothreat detection, PCR systems, infectious disease panels
Industry4 codes
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAJAIAL
Biothreat/Biocontainment & Select Agent Public Health Laboratories
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Molecular Diagnostics / In Vitro Diagnostics (IVD)
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Molecular Diagnostic Systems
TypeHardware Sales
Description

Sale of diagnostic instrument systems including BIOFIRE SPOTFIRE, FILMARRAY TORCH, and RAZOR Mk II PCR platforms. These systems serve as the hardware foundation for running proprietary test panels.

biofiredefense.com
2Diagnostic Test Panels
TypeOne Time License
Description

Sale of proprietary test panels and reagent kits including gastrointestinal, respiratory, biothreat, and tropical disease panels. These single-use consumables provide recurring revenue as tests are performed.

biofiredefense.com
3COVID-19 and Specialized Tests
TypeOne Time License
Description

Specialized diagnostic tests such as BioFire COVID-19 Test (EUA authorized) for SARS-CoV-2 detection, sold in packs of 6 or 30 tests.

biofiredefense.com
4Quality Control Products
TypeOne Time License
Description

External quality control materials including BIOFIRE SHIELD Control Kits designed for use with BioFire and SPOTFIRE systems, ensuring consistent performance and meeting accreditation requirements.

biofiredefense.com
5Software Modules
TypeLicensing Royalties
Description

Pouch modules and Electronic Report Modules (ERM) software downloads for BioFire systems, enabling specific test functionality and LIS integration.

biofiredefense.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BioFire Defense designs, manufactures, and sells PCR-based molecular diagnostic instruments and proprietary test panels for syndromic infectious disease detection and biothreat identification. Its portfolio spans three core instrument platforms — the BIOFIRE SPOTFIRE point-of-care PCR, the BIOFIRE FILMARRAY TORCH high-throughput system, and the RAZOR Mk II portable field-deployable PCR — supported by single-use test panels (respiratory, gastrointestinal, biothreat, Global Fever, BioThreat-E), reagent kits, and BIOFIRE SHIELD external quality controls.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Results in approximately 45 minutes for BioFire SPOTFIRE COVID-19 Test
+2 more records
Product overview1 text field

BioFire Defense offers a portfolio of syndromic molecular diagnostic systems and biothreat detection solutions. The product ecosystem centers on three core instrument platforms: the BIOFIRE SPOTFIRE (point-of-care PCR), BIOFIRE FILMARRAY TORCH (high-throughput molecular diagnostic), and RAZOR Mk II (portable field-deployable PCR). These systems run compatible test panels including Respiratory, Gastrointestinal, BioThreat, Global Fever, Meningitis/Encephalitis, Blood Culture Identification, Pneumonia, and Tropical Fever panels. Quality control is maintained through BIOFIRE SHIELD Control Kits. Software modules (pouch modules and ERM) enable instrument operation and LIS data transfer. The company operates under bioMérieux ownership and serves Clinical-IVD, High Consequence-IVD, CBRN, and External Quality Control market segments.

Product and service1 record
1BIOFIRE SPOTFIRE
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

BioFire Defense is a subsidiary backed by bioMérieux, a major global in vitro diagnostics company. The company references the bioMérieux Global Code of Conduct Manual and Corruption Prevention Manual in their business terms. The parent company provides institutional backing, global reach, and access to the broader bioMérieux diagnostic ecosystem.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

908 Devices provides handheld mass spectrometry and CBRN/biothreat detection tools used by military and first responders, overlapping with BioFire Defense's RAZOR Mk II CBRN mission.

TypeEmerging player
Description

T2 Biosystems develops rapid molecular diagnostics for sepsis and other bloodstream infections, representing an emerging player with adjacent molecular diagnostic capability to BioFire Defense's portfolio.

TypeDirect peer
Description

Cepheid (a Danaher company) is the leading molecular diagnostics PCR platform with the GeneXpert system, directly comparable to BioFire Defense's FilmArray TORCH and SPOTFIRE for syndromic infectious disease testing in clinical and decentralized settings.

TypeDirect peer
Description

BioFire Diagnostics is the sister company within bioMérieux that commercializes the FilmArray platform in clinical markets; it shares core technology lineage with BioFire Defense and operates an overlapping multiplex PCR syndromic testing menu.

TypeDirect peer
Description

Hologic's Panther Fusion and Panther systems are molecular diagnostic PCR platforms competing in syndromic infectious disease testing with menus overlapping BioFire Defense's respiratory, GI, and biothreat panels.

TypeDirect peer
Description

QIAGEN's QIAstat-Dx is a direct molecular PCR syndromic testing competitor to BioFire Defense's FilmArray/SPOTFIRE, with comparable sample-to-answer syndromic panels for respiratory and GI infections.

7Abbott Molecular
TypeBroad incumbent
Description

Abbott operates the m2000 and ID NOW molecular diagnostic platforms, serving as a broad incumbent in PCR-based infectious disease testing with much larger global scale than BioFire Defense.

TypeBroad incumbent
Description

Roche's cobas Liat is a rapid point-of-care PCR system directly comparable to BioFire Defense's SPOTFIRE for fast infectious disease detection in decentralized clinical settings.

TypeDirect peer
Description

BD's BD MAX system and associated molecular panels compete with BioFire Defense in syndromic infectious disease testing, particularly for enteric and respiratory pathogens in clinical labs.

TypeDirect peer
Description

QuidelOrtho's Sofia and Savanna platforms offer rapid molecular and immunoassay diagnostics, providing overlapping point-of-care infectious disease testing comparable to BioFire Defense's SPOTFIRE.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioFire Defense

Molecular Diagnostics / In Vitro Diagnostics (IVD)biofiredefense.com

BioFire Defense, a Salt Lake City-based subsidiary of bioMérieux, develops multiplex PCR-based molecular diagnostic systems (SPOTFIRE, FILMARRAY TORCH, RAZOR Mk II) and proprietary test panels for syndromic infectious disease testing and biothreat detection, serving U.S. government, military, public health, and first responder markets globally.

What BioFire Defense does

BioFire Defense, LLC is a privately held molecular diagnostics company headquartered in Salt Lake City, Utah, and operates as a wholly-owned subsidiary of the French in vitro diagnostics major bioMérieux. Founded in 2001, the company designs, manufactures, and sells PCR-based diagnostic instruments and proprietary test panels focused on two tightly related markets: syndromic infectious disease testing in clinical and public health laboratories, and field-deployable biothreat detection for military, first responder, and biosurveillance customers.

Its product architecture centers on three instrument platforms: the BIOFIRE SPOTFIRE point-of-care PCR device (results in approximately 45 minutes), the BIOFIRE FILMARRAY TORCH high-throughput laboratory system, and the battery-powered RAZOR Mk II portable PCR system, which detects up to 10 biothreat agents in roughly 30 minutes. These instruments run a menu of single-use, freeze-dried reagent pouches covering respiratory, gastrointestinal, biothreat, global fever, meningitis/encephalitis, blood culture identification, pneumonia, and tropical disease panels. The company's revenue model combines upfront instrument sales with high-margin recurring consumables and software module sales (pouch modules and Electronic Report Modules for LIS integration), supplemented by BIOFIRE SHIELD external quality control kits.

BioFire Defense goes to market through three channels: direct enterprise sales (phone-based and via the military E-CAT procurement system) for U.S. government and defense customers, a global distributor network for international markets, and a B2B e-commerce storefront. Its customer base is concentrated in government, military, public health laboratories, and CBRN/biosurveillance end users, with regulatory moats including FDA Emergency Use Authorizations and compliance with FAR/DFAR and FAR-HHSAR clauses that position the company for BARDA and Department of Defense contract work. The business is protected by a portfolio of at least nine registered patents and several registered trademarks spanning instruments, panels, control kits, and chemistry.

BioFire Defense firmographics

Firmographics
Name
BioFire Defense
Legal name
BioFire Defense, LLC
Website
https://biofiredefense.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
101–250 employees
Short description
BioFire Defense, a Salt Lake City-based subsidiary of bioMérieux, develops multiplex PCR-based molecular diagnostic systems (SPOTFIRE, FILMARRAY TORCH, RAZOR Mk II) and proprietary test panels for syndromic infectious disease testing and biothreat detection, serving U.S. government, military, public health, and first responder markets globally.
Ownership category
akta.pro rank

BioFire Defense industry classification

Industry
Product category
Molecular Diagnostics / In Vitro Diagnostics (IVD)
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAJAIAL
Biothreat/Biocontainment & Select Agent Public Health Laboratories
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks

Keywords

  • Molecular diagnostics
  • Syndromic testing
  • Biothreat detection
  • PCR systems
  • Infectious disease panels

Where BioFire Defense is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioFire Defense business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Others

Revenue model

  1. Molecular Diagnostic Systems: Sale of diagnostic instrument systems including BIOFIRE SPOTFIRE, FILMARRAY TORCH, and RAZOR Mk II PCR platforms. These systems serve as the hardware foundation for running proprietary test panels.
  2. Diagnostic Test Panels: Sale of proprietary test panels and reagent kits including gastrointestinal, respiratory, biothreat, and tropical disease panels. These single-use consumables provide recurring revenue as tests are performed.
  3. COVID-19 and Specialized Tests: Specialized diagnostic tests such as BioFire COVID-19 Test (EUA authorized) for SARS-CoV-2 detection, sold in packs of 6 or 30 tests.
  4. Quality Control Products: External quality control materials including BIOFIRE SHIELD Control Kits designed for use with BioFire and SPOTFIRE systems, ensuring consistent performance and meeting accreditation requirements.
  5. Software Modules: Pouch modules and Electronic Report Modules (ERM) software downloads for BioFire systems, enabling specific test functionality and LIS integration.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

BioFire Defense product offering

Product offering

Core offering

BioFire Defense designs, manufactures, and sells PCR-based molecular diagnostic instruments and proprietary test panels for syndromic infectious disease detection and biothreat identification. Its portfolio spans three core instrument platforms — the BIOFIRE SPOTFIRE point-of-care PCR, the BIOFIRE FILMARRAY TORCH high-throughput system, and the RAZOR Mk II portable field-deployable PCR — supported by single-use test panels (respiratory, gastrointestinal, biothreat, Global Fever, BioThreat-E), reagent kits, and BIOFIRE SHIELD external quality controls.

Product overview

BioFire Defense offers a portfolio of syndromic molecular diagnostic systems and biothreat detection solutions. The product ecosystem centers on three core instrument platforms: the BIOFIRE SPOTFIRE (point-of-care PCR), BIOFIRE FILMARRAY TORCH (high-throughput molecular diagnostic), and RAZOR Mk II (portable field-deployable PCR). These systems run compatible test panels including Respiratory, Gastrointestinal, BioThreat, Global Fever, Meningitis/Encephalitis, Blood Culture Identification, Pneumonia, and Tropical Fever panels. Quality control is maintained through BIOFIRE SHIELD Control Kits. Software modules (pouch modules and ERM) enable instrument operation and LIS data transfer. The company operates under bioMérieux ownership and serves Clinical-IVD, High Consequence-IVD, CBRN, and External Quality Control market segments.

Differentiator

Problem solved

Functional benefit

Products and services

  • BIOFIRE SPOTFIRE

Quantifiable outcome

  • Results in approximately 45 minutes for BioFire SPOTFIRE COVID-19 Test
  • +2 more outcomes

Companies that use BioFire Defense

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

BioFire Defense technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature7 records

BioFire Defense partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • bioMérieuxcoreOthersBioFire Defense is a subsidiary backed by bioMérieux, a major global in vitro diagnostics company. The company references the bioMérieux Global Code of Conduct Manual and Corruption Prevention Manual in their business terms. The parent company provides institutional backing, global reach, and access to the broader bioMérieux diagnostic ecosystem.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

BioFire Defense competitors and assessment

Company assessment

Emerging players

  • 908 Devices: 908 Devices provides handheld mass spectrometry and CBRN/biothreat detection tools used by military and first responders, overlapping with BioFire Defense's RAZOR Mk II CBRN mission.
  • T2 Biosystems: T2 Biosystems develops rapid molecular diagnostics for sepsis and other bloodstream infections, representing an emerging player with adjacent molecular diagnostic capability to BioFire Defense's portfolio.

Direct peers

  • Cepheid: Cepheid (a Danaher company) is the leading molecular diagnostics PCR platform with the GeneXpert system, directly comparable to BioFire Defense's FilmArray TORCH and SPOTFIRE for syndromic infectious disease testing in clinical and decentralized settings.
  • BioFire Diagnostics (bioMérieux): BioFire Diagnostics is the sister company within bioMérieux that commercializes the FilmArray platform in clinical markets; it shares core technology lineage with BioFire Defense and operates an overlapping multiplex PCR syndromic testing menu.
  • Hologic: Hologic's Panther Fusion and Panther systems are molecular diagnostic PCR platforms competing in syndromic infectious disease testing with menus overlapping BioFire Defense's respiratory, GI, and biothreat panels.
  • QIAGEN: QIAGEN's QIAstat-Dx is a direct molecular PCR syndromic testing competitor to BioFire Defense's FilmArray/SPOTFIRE, with comparable sample-to-answer syndromic panels for respiratory and GI infections.
  • Becton Dickinson (BD): BD's BD MAX system and associated molecular panels compete with BioFire Defense in syndromic infectious disease testing, particularly for enteric and respiratory pathogens in clinical labs.
  • QuidelOrtho: QuidelOrtho's Sofia and Savanna platforms offer rapid molecular and immunoassay diagnostics, providing overlapping point-of-care infectious disease testing comparable to BioFire Defense's SPOTFIRE.

Broad incumbents

  • Abbott Molecular: Abbott operates the m2000 and ID NOW molecular diagnostic platforms, serving as a broad incumbent in PCR-based infectious disease testing with much larger global scale than BioFire Defense.
  • Roche Diagnostics: Roche's cobas Liat is a rapid point-of-care PCR system directly comparable to BioFire Defense's SPOTFIRE for fast infectious disease detection in decentralized clinical settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BioFire Defense social profiles

Digital presence

BioFire Defense compliance and trust

Trust signal

Compliance4 records

BioFire Defense financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioFire Defense leadership team

Management profile

Number of profiles

Profiles1 record

BioFire Defense funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioFire Defense M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioFire Defense

What does BioFire Defense do?

BioFire Defense designs, manufactures, and sells PCR-based molecular diagnostic instruments and proprietary test panels for syndromic infectious disease detection and biothreat identification. Its portfolio spans three core instrument platforms — the BIOFIRE SPOTFIRE point-of-care PCR, the BIOFIRE FILMARRAY TORCH high-throughput system, and the RAZOR Mk II portable field-deployable PCR — supported by single-use test panels (respiratory, gastrointestinal, biothreat, Global Fever, BioThreat-E), reagent kits, and BIOFIRE SHIELD external quality controls.

Is BioFire Defense a public or private company?

BioFire Defense is a private company. It is classified as corporate owned and is currently operating.

When was BioFire Defense founded?

BioFire Defense was founded in 2001. It employs 101 to 250 people.

Where is BioFire Defense based?

BioFire Defense is headquartered in Salt Lake City, United States, in the North America region.

How does BioFire Defense make money?

Five revenue lines are on record. Molecular Diagnostic Systems are the primary driver. The others are diagnostic Test Panels, COVID-19 and Specialized Tests, quality Control Products and software Modules.

Who are BioFire Defense's main competitors?

Emerging players on record are 908 Devices and T2 Biosystems. Direct peers are Cepheid, BioFire Diagnostics (bioMérieux), Hologic, QIAGEN, Becton Dickinson (BD) and QuidelOrtho. Broad incumbents are Abbott Molecular and Roche Diagnostics.

Does BioFire Defense have an API?

No public API is recorded for BioFire Defense.

What industry is BioFire Defense in?

BioFire Defense's product category is Molecular Diagnostics / In Vitro Diagnostics (IVD). Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
KSL NewsHow a Utah company is aiding the fight against EbolaBioFire Defense in Utah developed an FDA-approved test panel for Ebola, approved in 2023. The panel detects multiple diseases, including four known Ebola strains, and is being ramped up to meet demand from outbreaks in Congo and Uganda. As of June 10, CDC reported 676 confirmed cases and 136 deaths in Congo.MarketScreenerWhat Bundibugyo Ebola vaccines and treatments are under developmentGlobal health authorities are assessing experimental vaccines and treatments for the Bundibugyo Ebola outbreak in the DRC, which has caused about 550 cases and 101 deaths. The WHO prioritized candidates like rVSV and ChAdOx1 vaccines, with CEPI funding up to $8.6 million, and antibody therapies such as MBP134 and maftivimab. Most treatments have not been tested in humans and would require emergency authorization.TechbuzznewsBioHive Live 2026: Utah's Life Sciences Leaders Share Stories of Technology, Resilience, and Human ImpactBioHive Live 2026 took place on April 16, 2026, in Draper, Utah, drawing 800-900 attendees. Keynote speakers John Harris and Tracy Milgram shared stories of technology and community impact. The event is part of BioHive Week, with additional programming through April 17.www.army.milUSAMMDA Announces FDA 510 (k) Clearance of Rapid Diagnostic Test for COVID-19USAMMDA and BioFire Defense announced FDA 510(k) clearance for BioFire's COVID-19 Test 2, which detects SARS-CoV-2 in about 45 minutes. The test is the second FDA-approved COVID-19 diagnostic, following the BioFire Respiratory Panel 2.1. BioFire is adding four additional assays to detect variants, including omicron.FrontiersFirst Movers in Molecular Detection: Case Comparison on Harnessing Research and Development, Industry, and EntrepreneurshipA panel discussion from the 2020 ASM Biothreats conference compared the strategies of two molecular detection pioneers, BioFire Defense and Mammoth Biosciences, highlighting their technological leadership and rapid response to the COVID-19 pandemic. The article details how these companies leveraged specific technologies—air thermocycling qPCR for BioFire and CRISPR-Cas proteins for Mammoth—to develop diagnostic assays during the outbreak. It further analyzes the challenges and opportunities within the biodefense diagnostics market, emphasizing the importance of public-private partnerships and sustained R&D investment.www.army.milJPEO-CBRND Works with Industry to Develop COVID-19 Diagnostic TestsThe Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) collaborated with industry partners to rapidly develop COVID-19 diagnostic tests under FDA Emergency Use Authorization. Molecular diagnostics company Cepheid Inc. received EUA on March 20 for its rapid molecular test designed for GeneXpert systems, while BioFire Defense, LLC received EUA on March 23 for its test used with FilmArray and FilmArray Torch systems. Both technologies provide rapid point-of-care COVID-19 diagnostic capability for U.S. military forces and the civilian population.PrwebBioFire Defense Receives James S. Cogswell Award for Outstanding Industrial Security ExcellenceBioFire Defense, a bioMérieux affiliate, received the 2019 James S. Cogswell Outstanding Industrial Achievement Award from the DoD's Defense Security Service. The Salt Lake City facility was selected as one of 51 recipients from over 13,000 defense contractors, recognizing its security program's compliance with National Industrial Security Program requirements.The Salt Lake TribuneLive anthrax? Not a big deal, says the Utah lab that got someBioFire Defense in Utah received live anthrax from Dugway Proving Ground, but the company's vice president said all safety protocols were followed and no contamination occurred. The anthrax was contained in tubes or a laboratory hood, and no one was sickened. The company said the mistake did not significantly affect its revenue.PR Newswire APACBioFire Defense, a bioMerieux Company, Receives Prestigious Frost & Sullivan's 2014 Global New Product Innovation Award for its FilmArray(R) Ebola TestBioFire Defense received Frost & Sullivan's 2014 Global New Product Innovation Award for its FilmArray Ebola test. The test delivers results in one hour, reducing testing time and enabling faster treatment decisions. The company is prepared to work with local authorities to ensure availability in countries needing clinical testing.